A Population-Based Analysis of Laboratory Abnormalities During Isotretinoin Therapy for Acne Vulgaris
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine the incidence of abnormal laboratory test results among isotretinoin users. DESIGN: Retrospective cohort. SETTING: Comprehensive managed care health plan in Northern California. PARTICIPANTS: The study population comprised 13 772 patients aged 13 to 50 years with acne, undergoing oral isotretinoin therapy between March 1995 and September 2002. MAIN OUTCOME MEASURES: Laboratory values for serum triglyceride, total cholesterol, and liver transaminase levels; white blood cell count, hemoglobin level, and platelet count; and frequency of abnormal laboratory results by severity grade as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. RESULTS: Substantial increases in the cumulative incidence of abnormalities were seen in serum lipid and transaminase levels, but not in hematologic parameters, during isotretinoin treatment compared with the baseline period. The cumulative incidence of new abnormalities in patients with normal values at baseline was 44% for triglyceride level, 31% for total cholesterol level, and 11% for transaminase level. Moderate to severe abnormalities in lipid and transaminase levels were generally transient and reversible. New abnormalities in hematological test results were uncommon. CONCLUSIONS: The incidence of abnormally high serum lipid levels during isotretinoin treatment may be greater than previously estimated. Elevations in transaminase level are generally mild. Normal baseline values of serum lipid and transaminase levels do not preclude the development of new abnormalities during isotretinoin treatment. Routine monitoring of white blood cell count, hemoglobin level, and platelet count during isotretinoin therapy may be of little utility without clinical suspicion of an abnormality. The clinical significance of laboratory abnormalities during isotretinoin therapy remains to be determined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Krieger, N. (1992) · American Journal of Public Health · doi:10.2105/ajph.82.5.703 · Cited by 1,654 · cited 1×
“The health plan membership is ethnically and socioeconomically heterogeneous and generally representative of the San Francisco Bay Area population, although the lowest and highest strata of income are somewhat underrepresented.(13) The KPNC maintains comprehensive databases of such medical information on its membershi…”
BackgroundPrevention of Skin Cancer in Xeroderma Pigmentosum with the Use of Oral Isotretinoin
Kraemer, K. H., DiGiovanna, J. J., Moshell, A. N., Tarone, R. E., & Peck, G. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806233182501 · Cited by 575
Common Terminology Criteria for Adverse Events v3.0 (CTCAE)
(2008) · Principles and Practice of Clinical Trial Medicine · doi:10.1016/b978-0-12-373695-6.00022-3 · Cited by 457
Retinoid therapy of high-risk neuroblastoma
Reynolds, C. P., Matthay, K. K., Villablanca, J. G., & Maurer, B. J. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00108-3 · Cited by 330
Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne.
Bershad, S., Rubinstein, A., Paterniti, J. R., Le, N.-A., Poliak, S. C., Heller, B., Ginsberg, H. N., Fleischmajer, R., & Brown, W. V. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510173131604 · Cited by 217 · cited 1×
“6% to 32%.(8,9,11,12) Limited sample sizes diminish the precision of these studies’ estimates, and the lack of standard criteria for defining abnormal values among these studies makes them difficult to compare.”
BackgroundRodondi, N., Darioli, R., Ramelet, A.-A., Hohl, D., Lenain, V., Perdrix, J., Wietlisbach, V., Riesen, W. F., Walther, T., Medinger, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-8-200204160-00007 · Cited by 112 · cited 1×
“Patients with acne who develop large increases in triglyceride levels during isotretinoin therapy are at increased risk for future hyperlipidemia and the metabolic syndrome.(20,21) We plan to examine the incidence of adverse clinical outcomes in a future analysis.”
BackgroundImproving Safety Reporting from Randomised Trials
Ioannidis, J. P. A., & Lau, J. (2002) · Drug Safety · doi:10.2165/00002018-200225020-00002 · Cited by 101 · cited 1×
“Standardized grading scales have been considered prerequisites for the improvement of adverse event reporting in clinical trials.(17) There is no established grading system for laboratory abnormalities specifically for dermatologic treatments.”
BackgroundBARTH, J. H., MACDONALD-HULL, S. P., MARK, J., JONES, R. G., & CUNLIFFE, W. J. (1993) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1993.tb03336.x · Cited by 95 · cited 3×
“In addition, differences in dietary practices may contribute to the discrepancies in serum lipid level abnormalities seen between our study and those conducted in other countries.(8,9,12) Overall, the cumulative incidence of new abnormalities in liver transaminase level was low (11%), and most elevations were mild (91…”
BackgroundResultIsotretinoin and Acne in Practice: A Prospective Analysis of 188 Cases over 9 Years
Lehucher-Ceyrac, D., & Weber-Buisset, M. J. (2009) · Dermatology · doi:10.1159/000247322 · Cited by 82 · cited 1×
“O RAL ISOTRETINOIN IS CURrently the most effective acne treatment available, with reported long-term remission rates as high as 89%.(1) Case reports of such systemic complications as pancreatitis,(2-4) drug-induced hepatotoxicity,(5) leukopenia,(6) and thrombocytopenia(7) have prompted the widespread practice of frequ…”
BackgroundPancreatitis Associated with Isotretinoin-lnduced Hypertriglyceridemia
Flynn, W. J., FREEMAN, P. G., & WICKBOLDT, L. G. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-1-63 · Cited by 67
Cited by
Management of Acne Vulgaris: A Review
Eichenfield, D. Z., Sprague, J., & Eichenfield, L. F. (2021) · JAMA · doi:10.1001/jama.2021.17633 · Cited by 389
Laboratory Monitoring During Isotretinoin Therapy for Acne: A Systematic Review and Meta-analysis
Lee, Y. H., Scharnitz, T. P., Muscat, J., Chen, A., Gupta-Elera, G., & Kirby, J. S. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.3091 · Cited by 120
“5-7 This meta-analysis showed that (1) isotretinoin is associated with a statistically significant change in the mean value of several laboratory tests (white blood cell count and hepatic and lipid panels), yet (2) the mean changes across a patient group did not meet a priori criteria for high-risk and (3) the proport…”
BackgroundBarbieri, J. S., Shin, D. B., Wang, S., Margolis, D. J., & Takeshita, J. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.06.025 · Cited by 87
Bagatin, E., Guadanhim, L. R. S., Enokihara, M. M. S. S., Sanudo, A., Talarico, S., Miot, H. A., & Gibson, L. (2014) · International Journal of Dermatology · doi:10.1111/ijd.12191 · Cited by 52
Isotretinoin Laboratory Monitoring in Acne Treatment: A Delphi Consensus Study
Xia, E., Han, J., Faletsky, A., Baldwin, H., Beleznay, K., Bettoli, V., Dréno, B., Goh, C. L., Stein Gold, L., Gollnick, H., et al. (2022) · JAMA Dermatology · doi:10.1001/jamadermatol.2022.2044 · Cited by 40
Affleck, A., Jackson, D., Williams, H. C., Chavez, P., & Albrecht, J. (2022) · British Journal of Dermatology · doi:10.1111/bjd.21840 · Cited by 17
Metadata
- Authors
- Zane, L. T., Leyden, W. A., Marqueling, A. L., & Manos, M. M.
- Venue
- Archives of Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2006-08-01
- Volume
- 142
- Issue
- 8
- Pages
- 1016-22
- ISSN
- 0003-987X (ISSN-L)
- OpenAlex
- W1972778383
- Cited by
- 183
- References
- 19
- FWCI
- 6.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.